Dosimetry-Based Consideration on Remission and Relapse after Therapy with 223Ra-Dichloride in Castration-Resistant Prostate Cancer (CRPC) with Bone Metastases. A Case Report.
Diagnostics (Basel)
; 8(1)2018 Feb 27.
Article
en En
| MEDLINE
| ID: mdl-29495541
ABSTRACT
Here, we present the case of a 64-year-old male patient diagnosed with castration-resistant prostate cancer (CRPC) with bone metastasis, treated with abiraterone prednisone/prednisolone in combination with 223Ra-dichloride therapy, who had remission and a subsequent relapse of bone metastasis on repeated bone scans after therapy. We also discuss the possibility of continuing the 223Ra-dichloride therapy over the six planned administrations by administering other cycles at the same dose or at higher doses, if shown to be devoid of a significant increase in side effects, based on dosimetry considerations.
Texto completo:
1
Banco de datos:
MEDLINE
Idioma:
En
Revista:
Diagnostics (Basel)
Año:
2018
Tipo del documento:
Article
País de afiliación:
Italia